Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
The aggregate gross proceeds to Benitec from the underwritten offering and the concurrent registered direct offering are expected to be approximately $30 million, prior to deducting underwriting ...
BioPharma Dive34m
Character Biosciences raises $93M with an eye on vision loss drugs
The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...
Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology Immunotherapies
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, March 25, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical ...